434 related articles for article (PubMed ID: 37197024)
1. Latest insights in disease-modifying osteoarthritis drugs development.
Li S; Cao P; Chen T; Ding C
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231169839. PubMed ID: 37197024
[TBL] [Abstract][Full Text] [Related]
2. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
Oo WM; Little C; Duong V; Hunter DJ
Drug Des Devel Ther; 2021; 15():2921-2945. PubMed ID: 34262259
[TBL] [Abstract][Full Text] [Related]
3. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).
Oo WM; Hunter DJ
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090297. PubMed ID: 35619876
[TBL] [Abstract][Full Text] [Related]
4. Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.
Li J; Wang X; Ruan G; Zhu Z; Ding C
Expert Opin Investig Drugs; 2021 Sep; 30(9):923-930. PubMed ID: 34427483
[TBL] [Abstract][Full Text] [Related]
5. Anticytokine therapy for osteoarthritis: evidence to date.
Malemud CJ
Drugs Aging; 2010 Feb; 27(2):95-115. PubMed ID: 20104937
[TBL] [Abstract][Full Text] [Related]
6. New Trends in Pharmacological Treatments for Osteoarthritis.
Cai X; Yuan S; Zeng Y; Wang C; Yu N; Ding C
Front Pharmacol; 2021; 12():645842. PubMed ID: 33935742
[TBL] [Abstract][Full Text] [Related]
7. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
[TBL] [Abstract][Full Text] [Related]
8. Targeting macrophage polarization as a promising therapeutic strategy for the treatment of osteoarthritis.
Wang W; Chu Y; Zhang P; Liang Z; Fan Z; Guo X; Zhou G; Ren W
Int Immunopharmacol; 2023 Mar; 116():109790. PubMed ID: 36736223
[TBL] [Abstract][Full Text] [Related]
9. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
[TBL] [Abstract][Full Text] [Related]
10. Prospects for Therapies in Osteoarthritis.
Ghouri A; Conaghan PG
Calcif Tissue Int; 2021 Sep; 109(3):339-350. PubMed ID: 32055890
[TBL] [Abstract][Full Text] [Related]
11. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
[TBL] [Abstract][Full Text] [Related]
13. Emerging pharmaceutical therapies for osteoarthritis.
Latourte A; Kloppenburg M; Richette P
Nat Rev Rheumatol; 2020 Dec; 16(12):673-688. PubMed ID: 33122845
[TBL] [Abstract][Full Text] [Related]
14. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Rheum Dis Clin North Am; 2024 Aug; 50(3):483-518. PubMed ID: 38942581
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.
Davies PS; Graham SM; MacFarlane RJ; Leonidou A; Mantalaris A; Tsiridis E
Expert Opin Investig Drugs; 2013 Apr; 22(4):423-41. PubMed ID: 23409708
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
Vrouwe JPM; Burggraaf J; Kloppenburg M; Stuurman FE
Osteoarthr Cartil Open; 2021 Dec; 3(4):100212. PubMed ID: 36474768
[TBL] [Abstract][Full Text] [Related]
17. Sprifermin: Effects on Cartilage Homeostasis and Therapeutic Prospects in Cartilage-Related Diseases.
Song Z; Li Y; Shang C; Shang G; Kou H; Li J; Chen S; Liu H
Front Cell Dev Biol; 2021; 9():786546. PubMed ID: 34970547
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future.
Karsdal MA; Michaelis M; Ladel C; Siebuhr AS; Bihlet AR; Andersen JR; Guehring H; Christiansen C; Bay-Jensen AC; Kraus VB
Osteoarthritis Cartilage; 2016 Dec; 24(12):2013-2021. PubMed ID: 27492463
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.
Cho Y; Jeong S; Kim H; Kang D; Lee J; Kang SB; Kim JH
Exp Mol Med; 2021 Nov; 53(11):1689-1696. PubMed ID: 34848838
[TBL] [Abstract][Full Text] [Related]
20. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.
Jotanovic Z; Mihelic R; Sestan B; Dembic Z
Curr Drug Targets; 2014 Jun; 15(6):635-61. PubMed ID: 24597569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
